50S ribosomal subunit Inhibitors
3 drugsAbout 50S ribosomal subunit
The 50S ribosomal subunit is a critical component of bacterial ribosomes, essential for protein synthesis. Disrupting its function inhibits bacterial growth, making it a well-established antibacterial target.
Targeting the 50S ribosomal subunit is a proven antibacterial strategy, though no genetic evidence directly links subunit variations to disease susceptibility.
Three small molecule drugs, including ERYTHROMYCIN LACTOBIONATE, ERYTHROCIN, and ERY-TAB, target this subunit. These drugs are marketed by GLAND, Pfizer and PHARMOBEDIENT.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Pre-term Premature Rupture of Membranes with only 1 trials.
Top 50S ribosomal subunit Drugs
The competitive landscape includes three companies with approved drugs: GLAND, Pfizer, and PHARMOBEDIENT.
Limited number of players suggests moderate barriers to entry, but also less competition.
50S ribosomal subunit Drug Modality Landscape
Modalities
Routes of Administration
50S ribosomal subunit is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore alternative modalities like peptides or biologics to differentiate from existing therapies.
50S ribosomal subunit Clinical Trials 31 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 15 | 15 | 0 | 0 | 100% |
| Phase 2 | 7 | 5 | 2 | 0 | 71% |
| Phase 3 | 4 | 1 | 2 | 1 | 33% |
| Phase 4 | 5 | 2 | 0 | 2 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
50S ribosomal subunit Drug Approval Timeline (1982 - 1989)
The first drug was approved in 1964 (ERYTHROCIN), and the most recent in 1989 (ERYTHROMYCIN LACTOBIONATE).
The long gap since the last approval indicates potential saturation or challenges in developing new drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 27 clinical trials targeting 50S ribosomal subunit.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities